EP Wealth Advisors LLC Purchases Shares of 1,608 United Therapeutics Co. (NASDAQ:UTHR)

EP Wealth Advisors LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,608 shares of the biotechnology company's stock, valued at approximately $576,000.

A number of other hedge funds have also recently bought and sold shares of the company. ClariVest Asset Management LLC grew its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 42 shares during the last quarter. USA Financial Formulas purchased a new position in shares of United Therapeutics in the third quarter worth approximately $33,000. Brooklyn Investment Group purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $33,000. V Square Quantitative Management LLC acquired a new position in United Therapeutics in the 2nd quarter worth approximately $30,000. Finally, Innealta Capital LLC acquired a new stake in United Therapeutics during the 2nd quarter valued at $33,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Trading Down 0.2 %

United Therapeutics stock traded down $0.55 during trading hours on Thursday, reaching $361.61. 243,990 shares of the company were exchanged, compared to its average volume of 447,891. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock has a 50-day moving average of $369.59 and a 200 day moving average of $340.92. The firm has a market cap of $16.14 billion, a price-to-earnings ratio of 16.01, a PEG ratio of 1.07 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. During the same period in the previous year, the company earned $5.38 earnings per share. United Therapeutics's revenue for the quarter was up 22.9% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on UTHR. Wells Fargo & Company lifted their price target on United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a report on Tuesday, August 20th. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Argus boosted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Finally, TD Cowen lifted their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $370.86.

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 224 shares of the business's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72. Following the completion of the transaction, the director now owns 5,783 shares of the company's stock, valued at approximately $2,384,215.24. The trade was a 3.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 15,000 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $1,034,510.88. This represents a 85.34 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 119,340 shares of company stock worth $44,765,530. 11.90% of the stock is owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.